Why Precision Medicine?

 

  • A 2016 study showed that the percentage of cancer patients who achieved tumor shrinkage doubles when prescribed treatments matched to their genomic profile.

  • Comprehensive genomic profiling enables physicians to find more treatment options and select the most suitable treatment based on  genomic characteristics.

  • Using ACTOnco®+ comprehensive genomic profiling, 83.9% of the patients found corresponding treatment solutions.

 

% Achieved Tumor Shrinkage


Conventional Medicine
One-size-fits-all

Precision Medicine
Genotype-matched and personalized

Source: Genome Medicine (2016) 8:109

What We Offer

Comprehensive Genomic Profiling

ACTOnco®+ analyzes 440 genes to help physicians find more treatment options and identify the most suitable therapies. Treatment evaluation includes targeted therapy, immunotherapy, hormone therapy and chemotherapy.

Liquid Biopsy for Cancer Monitoring

ACTMonitor™analyzes tumor DNA circulating in blood stream to provide physicians with real-time monitoring of drug resistance, early detection of cancer recurrence and evaluation of treatment responses.

 

 

Patient Stories

To date I have done three rounds of Genomic Profiling Analysis semi-annually to monitor my liver tumor genes mutation activities. In case I have a recurrence, or develop a secondary cancer, I will stand a better chance to treat it at early stage.

 

Andrew Tay, MD
A liver cancer survivor in Singapore

More Patient Stories

About ACT Genomics

ACT Genomics empowers physicians with evidence-based genomic insights and partners with biopharma to accelerate drug development through biomarker discovery, patient stratification and comprehensive cancer molecular analysis. Our headquarters and CAP-accredited laboratory are located in Taiwan with offices in Singapore, Hong Kong and Japan.

 

83.9%
Found Treatment Solutions

75
Collaborating Hospitals

14
Biopharma & Research Partners

News

 

ACT Genomics Completed Another Round of Equity Financing

ACT Genomics is pleased to announce the completion of the latest round of equity financing from a group of international investors co-led by CLSA Capital Partners to support the establishment of new CAP-accredited lab in HK, as well as R&D effort.

Get to know more about ACT Genomics

E-newsletters

2018.Dec.05th

ACT Genomics December E-newsletter

2018 Vol.12

See More

Keep in Touch

Subscribe to ACT Genomics Newsletter to be connected to the latest precision medicine